Navigation Links
Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Date:8/19/2007

SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today reported financial results for the quarter ended June 30, 2007. Revenues for the second quarter of 2007 were $3.1 million, compared with revenues of $7.3 million for the second quarter of 2006. The net loss for the second quarter of 2007 was $8.2 million, or $0.21 per share, compared with a net loss of $3.2 million, or $0.11 per share, for the second quarter of 2006. The increase in net loss reflected a proactive reduction of contract manufacturing activity and higher spending for advancement of the company's independent development programs.

Based on anticipated activities for the remainder of 2007, including acceleration of the company's pandemic influenza vaccine program, the company is revising its projection to a full-year net loss of between $32 million and $37 million and a net cash burn for the full year, excluding equity investments, of $27 million to $32 million. Vical had cash and investments of $82 million at June 30, 2007.

Pandemic Influenza IND Allowed

-- Vical has received notification of Investigational New Drug (IND)

allowance for its Phase 1 trial of the company's

Vaxfectin(TM)-formulated pandemic influenza DNA vaccine, and now

expects to initiate the trial earlier than originally planned during

the second half of 2007.

Other Advances in Product Development Programs

-- The company's licensee, AnGes MG, Inc. (AnGes), reported positive

results following an interim efficacy evaluation in its Japanese Phase

3 angiogenesis trial of its gene-based Hepatocyte Growth Factor (HGF)

product candidate in patients with advanced peripheral arterial disease

(PAD). Based on the recommendation of an Independent Data Monitoring

Committee, AnGes ended the trial early and is preparing an application

for Japanese marketing approval.

-- Vical announced
'/>"/>

SOURCE Vical

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
4. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
7. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
8. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 20, 2015 Research and Markets( ... "Guide to Prepare Application Dossiers for Oversea ... Edition) " report to their offering. ... of segment market of the most growth potentiality, ... device manufacturers and producers to penetrate such market. ...
(Date:5/22/2015)... Today, Rhodes Pharmaceuticals L.P. announced that Aptensio ... for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will ... The announcement comes just one month ... Food and Drug Administration (FDA). ... capsule with an onset of effect of 1 ...
(Date:5/22/2015)... CITY, Calif. , May 22, 2015 ... pharmaceutical company focused on the development and commercialization of ... pain, today announced that interim chief executive officer ... Healthcare Conference and chief financial officer Tim Morris ... Conference. Details of the two presentations are as follows: ...
Breaking Medicine Technology:China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2
... LUCCA, Italy--(BUSINESS WIRE)--May 14, 2007 - Acceleron ... the,treatment of musculoskeletal, metabolic and cancer-related,diseases, today ... that demonstrated the ability of the compound ... mice and in murine models of,muscular dystrophy. ...
... WIRE)--May 14, 2007--Sciele Pharma, Inc.,(NASDAQ:SCRX) today announced the ... new Sular formulation. The study,results showed that the ... Sular. The new Sular formulation,utilizes SkyePharma's (LSE:SKP) patented ... dose of Sular for each of its,current doses. ...
Cached Medicine Technology:Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 2Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 2Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 4
(Date:5/22/2015)... Knoxville, TN (PRWEB) May 22, 2015 Power ... Andrew Drobeck for the 2015 race season. Drobeck is in ... also serves as a firefighter with the Missoula Fire Department ... and became a Pro in 2014. During his career, he ... as a Pro, Drobeck recorded top 10 finishes in all ...
(Date:5/22/2015)... The dentist in West ... they are now offering complimentary consultations to patients ... At consultations, patients can discuss their candidacy for ... treatments can achieve and whether alternative options are ... appointment. If treatments are chosen, patients can start ...
(Date:5/22/2015)... A Phase 3 French study, ... of Clinical Oncology (ASCO)’s annual meeting at the ... those patients who received bevacizumab in addition to ... (Avastin® Genentech, Inc.) is an antibody that blocks ... routinely used to treat many other cancers, including ...
(Date:5/22/2015)... AZ (PRWEB) May 22, 2015 In ... Olympics, Parker and Sons is offering to donate $5 ... installing an AC unit or water softening system. Customers ... behalf; Parker and Sons gets business; and the Special ... , The Special Olympics helps over 4.4 million athletes, ...
(Date:5/22/2015)... May 22, 2015 A new program ... experts in the field of Physical Therapy. , ... takes the mystery out of physical therapy and discusses ... of motion for a variety of ailments and injuries. ... a personalized exercise plan that enhances daily activities such ...
Breaking Medicine News(10 mins):Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2
... 12 The following was,issued today by the ... (NQF) Implementation Conference on Care,Coordination and 2008 Spring ... http://www.qualityforum.org ., March 26: Spring Membership Meeting. ... membership and leaders of the National Priorities,Partners, a ...
... who use ibuprofen for arthritis pain or other conditions ... second stroke undermine aspirins ability to act as an ... shown. , In a cohort of patients seen by ... 28 patients were identified as taking both aspirin and ...
... Impact Patient Health and Financial ... Performance of Pharmaceutical Companies, NEW YORK and LONDON, March ... per year and causing an,estimated 125,000 deaths per year in ... healthcare industry. Eularis has,responded to this problem with a new ...
... physicians from using Avastin, researchers say , , WEDNESDAY, March 12 ... cause kidney damage by doing what it,s supposed to -- ... whose generic name is bevacizumab, is the first member of ... off their blood supply. It does this by inhibiting the ...
... Downloadable ,Pocket, Films Help Increase Public Understanding ... 12 With the aging of the,population, ... epidemic,proportions by mid-century, creating massive and unsustainable ... families, and millions of lives,tragically lost to ...
... Race Central, the country,s,preeminent race timing organization, ... 5K run/walk ( http://www.VigorLatino5K.com ) to be,held at ... March,29, 2008. The Vigor Latino 5K run/walk will ... to take part in a local run/walk Health ...
Cached Medicine News:Health News:National Quality Forum Spring Conference; Leaders in Healthcare Quality to Focus on National Priorities and Care Coordination 2Health News:Ibuprofen destroys aspirin's positive effect on stroke risk 2Health News:Ibuprofen destroys aspirin's positive effect on stroke risk 3Health News:Eularis Exposes Hidden Barriers to Patient Adherence With New Pharmaceutical Industry Report 2Health News:Eularis Exposes Hidden Barriers to Patient Adherence With New Pharmaceutical Industry Report 3Health News:Doctors See How Cancer Drug Can Damage Kidneys 2Health News:Doctors See How Cancer Drug Can Damage Kidneys 3Health News:New Tools Boost Alzheimer's Awareness 2Health News:New Tools Boost Alzheimer's Awareness 3Health News:Race Central Launches Vigor Latino 5K Run/Walk, Promoting Hispanic Health, Fun and Fitness 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: